Mostrando 2 resultados de: 2
Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody
ArticleAbstract: The multiple-dose strategy with the monoclonal ior EGF/r3 antibody, in xenograft bearing nude mice,Palabras claves:Allometric scaling, Dosage regimen, Integrated pharmacokinetic-pharmacodynamic, Monoclonal antibody ior EGF/r3, Survival time, Tumor growth delayAutores:Alonso K., Alvarez D., Beausoleil I., Bécquer M.d.l.A., Castillo R., Duconge J., Fernández-Sánchez E.M., Matheu J., Tania Crombet, Valenzuela-Silva C.M., Vecino G.Fuentes:scopusTopical disposition of two strengths of a <sup>125</sup>I-rhEGF jelly in rat skin wounds
ArticleAbstract: Growth factors have proved to be an effective therapeutic strategy. However, some controversies havePalabras claves:125 I-rhEGF, Jelly, Non-linearity, Strength, Topical dispositionAutores:Aguilera A., Alfonso-Ortíz S., Alvarez D., Bécquer M.d.l.A., Duconge J., Estrada L., Eugenio Hardy, Fernández-Sánchez E.M., García-Pulpeiro O., Prats P.A., Rojas I., Valenzuela-Silva C.M.Fuentes:scopus